This article is more than 5 years old. Information may no longer be current.

FDA approves Hylaform dermal filler

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

SANTA BARBARA, Calif. — A hyaluronic-acid-based dermal filler has been granted marketing approval by U.S. regulators for the treatment of moderate to severe facial wrinkles and folds, including nasolabial folds, according to the companies marketing the product.

The substance, Hylaform gel, “has a proven record in countries around the world for nearly a decade,” said Hani Zeini, executive vice president for Inamed, which markets the product with Genzyme Corp.

Hylaform gel is a clear, colorless gel derived from purified hyaluronic acid, according to a press release from the companies. Genzyme developed and manufactures the product, and Inamed has exclusive worldwide marketing rights.

Late last year the Food and Drug Administration approved another hyaluronic-based product, Restylane, from Q-ed. For more information on these products, click here.